Assessment of Proactive Treatments in Patients With Wet Age-related Macular Degeneration (wAMD) Which Have Never Undergone Treatment of This Particular Disease

Sponsor
Bayer
Study ID
NCT03939767
Status
Completed

Conditions

  • Wet Age-related Macular Degeneration

Eligibility Criteria

Sex
ALL
Age
50 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Aflibercept (Eylea, BAY86-5321) — DRUG
    As prescribed by the treating physician according to the local label. No IVT aflibercept will be provided due to a nature of observational study.

Study Details

In this observational study researchers want to learn more about changes in visual acuity (clarity of vision) with proactive flexible treatments over time in patients suffering from wet age-related macular degeneration (wAMD) after decision to treat with Aflibercept (Eylea) was made. Wet AMD is an eye disease that progressively destroys the macula, the central portion of the retina, impairing central vision.

Key Dates

Start date
May 12, 2019
Status verified
Sep 2024
Primary completion
Jul 7, 2023
Completion
Oct 17, 2023

Study Design

Enrollment
1,563 participants (actual)

Arms

  • Arm: wAMD patients
    Patients with a diagnosis of wAMD and naïve to any treatment in the study eye will be enrolled after the decision by treating physician for IVT aflibercept therapy according to the local label.

Primary Outcome Measure

The change in BCVA (best corrected visual acuity) [ Time Frame: Baseline to 12 months ]

Related Studies